Stock Traders Buy High Volume of Ardelyx Put Options (NASDAQ:ARDX)

Key Points

• Traders bought 20,015 Ardelyx put options on Wednesday—about 466% above average volume—potentially reflecting increased hedging or bearish positioning, though options activity alone does not establish sentiment.
• Law firms reiterated a November 16 lead-plaintiff deadline for a securities class action concerning alleged revenue-outlook disclosures about XPHOZAH and IBSRELA. The claims are allegations, not findings.
• BTIG cut its price target to $11 from $14 but maintained a Buy rating; analysts’ average target is $13.60, compared with Ardelyx’s Wednesday closing price of $3.10.

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) saw unusually large options trading on Wednesday. Traders acquired 20,015 put options on the stock. This represents an increase of approximately 466% compared to the average volume of 3,538 put options.

Ardelyx News Summary

These are some of the ARDX news items that stood out recently:

• Negative Sentiment: Investors purchased 20,015 ARDX put options on Wednesday, about 466% above the reported average daily volume. The jump may signal increased hedging or bearish positioning, though options activity alone does not establish investors’ expectations.
• Negative Sentiment: Several law firms reiterated that November 16 is the lead-plaintiff deadline in a securities class action involving investors who bought Ardelyx shares during specified periods in 2025–2026. The notices cite allegations that the company maintained revenue outlooks for XPHOZAH and IBSRELA despite payer-access barriers; these are allegations, not findings. Repeated law-firm notices add legal and reputational uncertainty. Shareholder alert
• Negative Sentiment: BTIG’s price-target reduction is a less favorable revision, even though the firm kept its Buy rating.

Insider Buying and Selling

In related news, insider Laura Williams sold 10,739 shares of the firm's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $41,452.54. Following the completion of the transaction, the insider owned 367,456 shares of the company's stock, valued at $1,418,380.16. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Foster sold 8,562 shares of Ardelyx stock in a transaction on Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $33,049.32. Following the transaction, the insider owned 409,410 shares of the company's stock, valued at $1,580,322.60. The trade was a 2.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 126,059 shares of company stock worth $486,588 over the last three months. Corporate insiders own 5.30% of the company's stock.

Institutional Trading of Ardelyx

A number of large investors have recently made changes to their positions in the stock. CenterBook Partners LP lifted its position in Ardelyx by 29.0% during the third quarter. CenterBook Partners LP now owns 60,140 shares of the biopharmaceutical company's stock valued at $206,000 after purchasing an additional 13,536 shares during the period. Kestra Advisory Services LLC bought a new stake in Ardelyx in the 3rd quarter worth approximately $39,000. Chicago Partners Investment Group LLC grew its position in Ardelyx by 33.8% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 57,655 shares of the biopharmaceutical company's stock worth $178,000 after purchasing an additional 14,563 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Ardelyx during the 3rd quarter valued at $44,000. Finally, Profund Advisors LLC raised its stake in Ardelyx by 6.1% during the 3rd quarter. Profund Advisors LLC now owns 111,771 shares of the biopharmaceutical company's stock valued at $382,000 after buying an additional 6,433 shares during the last quarter. 58.92% of the stock is currently owned by institutional investors.

Ardelyx Stock Performance

Shares of NASDAQ:ARDX traded up $0.09 during midday trading on Wednesday, reaching $3.10. 803,746 shares of the company's stock traded hands, compared to its average volume of 4,336,836. The company has a market cap of $778.00 million, a price-to-earnings ratio of -14.07 and a beta of 0.79. The company has a debt-to-equity ratio of 1.54, a quick ratio of 3.26 and a current ratio of 3.45. Ardelyx has a one year low of $2.80 and a one year high of $8.40. The stock has a 50 day moving average of $3.32 and a 200 day moving average of $5.18.

Analysts Set New Price Targets

ARDX has been the topic of a number of analyst reports. BTIG Research dropped their price target on shares of Ardelyx from $14.00 to $11.00 and set a "buy" rating on the stock in a research note on Monday. HC Wainwright restated a "buy" rating and set a $13.00 price objective on shares of Ardelyx in a research note on Friday, August 7th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Ardelyx in a report on Friday, September 25th. Citigroup dropped their target price on shares of Ardelyx from $14.00 to $11.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. Finally, Piper Sandler cut their price target on shares of Ardelyx from $16.00 to $15.00 and set an "overweight" rating on the stock in a report on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Ardelyx has an average rating of "Moderate Buy" and an average target price of $13.60.

About Ardelyx

Ardelyx, Inc. is a biopharmaceutical company that develops and commercializes medicines for kidney and gastrointestinal diseases. Founded in 2007, the company has focused on treatments that work in the gastrointestinal tract, including therapies based on tenapanor. Ardelyx markets IBSRELA (tenapanor) in the United States for adults with irritable bowel syndrome with constipation. It also markets XPHOZAH (tenapanor) to help control serum phosphorus in adults with chronic kidney disease who are on dialysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.